About this item:

198 Views | 155 Downloads

Author Notes:

Lauren E. McCullough, PhD, MSPH, Department of Epidemiology, Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322 (e-mail: lauren.mccullough@emory.edu)

The authors gratefully acknowledge the contribution of the Greater-Atlanta Breast Cancer Task Force for their contribution to the development of this paper and unwavering efforts to reduce racial disparities in breast cancer mortality in Atlanta. The authors additionally acknowledge the contribution of Dr Timothy L. Lash for his support in the development of this project and manuscript.

KG reports serving on the advisory board with Pfizer and Lilly corporations and receives research funding to her institution from Pfizer, Calithera, and Merck. No other co-authors have conflicts of interest to declare.

Subjects:

Research Funding:

This project was supported, in part, by the AVON Foundation (01–2016-087), the Cancer Prevention and Control Research program, and the Winship Research Informatics shared resources, a core supported by the Winship Cancer Institute of Emory University.

The collection of cancer incidence data used in this study was supported by contract HHSN261201800003I, Task Order HHSN26100001 from the National Cancer Institute and cooperative agreement 5NU58DP003875-04 from the Centers for Disease Control and PRevention.

Keywords:

  • racial disparities
  • breast cancer
  • outcomes
  • non-Hispanic black
  • women
  • non-Hispanic white
  • patient characteristics
  • tumor
  • treatment
  • Atlanta
  • stage I–IV BC
  • hazard ratios

Racial disparities in breast cancer outcomes in the metropolitan Atlanta area: New insights and approaches for health equity

Show all authors Show less authors

Tools:

Journal Title:

JNCI Cancer Spectrum

Volume:

Volume 3, Number 3

Publisher:

, Pages pkz053-pkz053

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: Racial disparities in breast cancer (BC) outcomes persist where non-Hispanic black (NHB) women are more likely to die from BC than non-Hispanic white (NHW) women, and the extent of this disparity varies geographically. We evaluated tumor, treatment, and patient characteristics that contribute to racial differences in BC mortality in Atlanta, Georgia, where the disparity was previously characterized as especially large. Methods: We identified 4943 NHW and 3580 NHB women in the Georgia Cancer Registry with stage I-IV BC diagnoses in Atlanta (2010-2014). We used Cox proportional hazard regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) comparing NHB vs NHW BC mortality by tumor, treatment, and patient characteristics on the additive and multiplicative scales. We additionally estimated the mediating effects of these characteristics on the association between race and BC mortality. Results: At diagnosis, NHB women were younger-with higher stage, node-positive, and triple-negative tumors relative to NHW women. In age-adjusted models, NHB women with luminal A disease had a 2.43 times higher rate of BC mortality compared to their NHW counterparts (95% CI = 1.99 to 2.97). High socioeconomic status (SES) NHB women had more than twice the mortality rates than their white counterparts (HR = 2.67, 95% CI = 1.65 to 4.33). Racial disparities among women without insurance, in the lowest SES index, or diagnosed with triple-negative BC were less pronounced. Conclusions: In Atlanta, the largest racial disparities are observed in luminal tumors and most pronounced among women of high SES. More research is needed to understand drivers of disparities within these treatable features.

Copyright information:

© The Author(s) 2019. Published by Oxford University Press.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Export to EndNote